Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
68.11
-0.25 (-0.37%)
At close: Mar 3, 2026, 4:00 PM EST
68.70
+0.59 (0.87%)
After-hours: Mar 3, 2026, 7:35 PM EST
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.79M in the quarter ending September 30, 2025, a decrease of -51.13%. This brings the company's revenue in the last twelve months to $62.60M, down -32.79% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$62.60M
Revenue Growth
-32.79%
P/S Ratio
30.44
Revenue / Employee
$1,026,230
Employees
61
Market Cap
1.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 283.06M |
| Soleno Therapeutics | 190.41M |
| Syndax Pharmaceuticals | 172.35M |
| Recursion Pharmaceuticals | 74.68M |
| Ocular Therapeutix | 51.95M |
| Nuvation Bio | 26.75M |
| Relay Therapeutics | 15.36M |
| Celldex Therapeutics | 1.55M |
NKTR News
- 5 days ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - PRNewsWire
- 7 days ago - Nektar Therapeutics to Participate in Two Investor Conferences in March - PRNewsWire
- 13 days ago - Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
- 14 days ago - Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - PRNewsWire
- 18 days ago - Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 18 days ago - Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
- 20 days ago - Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PRNewsWire
- 20 days ago - Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga